Bears are Losing Control Over Nurix Therapeutics, Inc. (NRIX), Here's Why It's a 'Buy' NowZacks Investment Research • 01/09/23
Nurix Therapeutics Advances Promising Targeted Protein Modulation Pipeline and Outlines 2023 Strategic PrioritiesGlobeNewsWire • 01/09/23
Nurix Therapeutics to Present at 41st Annual J.P. Morgan Healthcare ConferenceGlobeNewsWire • 01/04/23
After Plunging -15.8% in 4 Weeks, Here's Why the Trend Might Reverse for Nurix Therapeutics, Inc. (NRIX)Zacks Investment Research • 12/28/22
Nurix Therapeutics Announces Clearance of Investigational New Drug Application for NX-5948 Supporting Plans to Expand Enrollment to U.S. Clinical SitesGlobeNewsWire • 12/15/22
Nurix Therapeutics Presents Positive Clinical Results from its Novel BTK Degrader (NX-2127) at the 64th American Society of Hematology (ASH) Annual MeetingGlobeNewsWire • 12/12/22
Nurix Therapeutics Announces Webcast to Review Data from its Phase 1 Clinical Trial of BTK Degrader, NX-2127, Presented at the 64th American Society of Hematology Annual MeetingGlobeNewsWire • 12/07/22
Nurix Announces Initial NX-1607 Phase 1 Data Presented at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) Demonstrating Targeted CBL-B Inhibition in Patients with Advanced MalignanciesGlobeNewsWire • 11/10/22
Nurix Announces DeTIL-0255 Scientific Presentations at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) and Successful Completion of DeTIL-0255 Phase 1 Safety Run-inGlobeNewsWire • 11/10/22
Wall Street Analysts Think Nurix Therapeutics, Inc. (NRIX) Could Surge 187%: Read This Before Placing a BetZacks Investment Research • 11/04/22
Nurix Therapeutics Announces Presentations at the 64th American Society of Hematology (ASH) Annual MeetingGlobeNewsWire • 11/03/22
Nurix Therapeutics Reports Case Study of Patient with Aggressive Non-Hodgkin's Lymphoma (NHL) Showing a Complete Clinical Response to NX-2127 at the 5th Annual Targeted Protein Degradation (TPD) SummitGlobeNewsWire • 10/26/22
Nurix Therapeutics Announces Presentations at the 5th Annual Targeted Protein Degradation (TPD) SummitGlobeNewsWire • 10/19/22
Nurix Therapeutics, Inc. (NRIX) Reports Q3 Loss, Lags Revenue EstimatesZacks Investment Research • 10/06/22
Nurix Therapeutics Reports Third Quarter Fiscal 2022 Financial Results and Provides a Corporate UpdateGlobeNewsWire • 10/06/22
Nurix Therapeutics Appoints Leading Industry Strategist Edward C. Saltzman to its Board of DirectorsGlobeNewsWire • 09/14/22
Nurix Therapeutics, Inc. (NRIX) Moves to Buy: Rationale Behind the UpgradeZacks Investment Research • 09/07/22
Nurix Therapeutics Reports Fiscal Second Quarter 2022 Financial Results and Provides a Corporate UpdateGlobeNewsWire • 07/07/22
Nurix Therapeutics Announces Clearance of Investigational New Drug Application For NX-1607 Supporting Plans to Expand Enrollment to U.S. Clinical SitesGlobeNewsWire • 06/30/22
Nurix Therapeutics Will Present Trial in Progress Posters for Two Clinical Programs at the 2022 Annual European Hematology Association (EHA) CongressGlobeNewsWire • 06/10/22
Nurix Therapeutics Will Present Trial in Progress Posters for Three Clinical Programs at the Annual Meeting of the American Society of Clinical Oncology (ASCO)GlobeNewsWire • 06/03/22